Abstract:Background and Aims Patients with chronic hepatitis B virus infection (CBI) with concurrent nonalcoholic fatty liver disease (NAFLD) is becoming increasingly common in clinical practice, and it is quite important to identify the etiology when hepatitis occurs. A noninvasive diagnostic model was constructed to identify patients who need antihepatitis B virus (HBV) therapies [histologic activity index (HAI) ≥ 4] in patients with CBI with concurrent NAFLD by analyzing clinical routine parameters. Approach and Results In total, 303 out of 502 patients with CBI with concurrent NAFLD proven by liver biopsy from January 2017 to December 2020 in the Tianjin Second People's Hospital were enrolled and they were divided into the HBV-related inflammation (HBV-I) group (HAI ≥ 4,176 cases) and the non-HBV-I group (HAI < 4,127 cases) according to hepatic pathology. The univariate analysis and multivariate logistic regression analysis were performed on the two groups of patients, and then the HBV-I model of patients with CBI with concurrent NAFLD was constructed. The areas under receiver operating characteristic curves (AUROCs) were used to evaluate the parameters of the regression formula. Another 115 patients with CBI with concurrent NAFLD proven by liver biopsy from January 2021 to January 2022 were enrolled as the validation group. There were some statistical differences in demographic data, biochemical indicators, immune function, thyroid function, virology indicator, and blood routine indicators between the two groups ( P < 0.05) and liver stiffness measurement (LSM) in the HBV-I group was significantly higher than those in the non-HBV-I group ( P < 0.05). While controlled attenuation parameters (CAP) in the HBV-I group were lower than those in the non-HBV-I group ( P < 0.05); (2) We developed a novel model by logistic regression analysis: HBV-I = −0.020 × CAP + 0.424 × LSM + 0.376 × lg (HBV DNA) + 0.049 × aspartate aminotransferase (AST) and the accuracy rate was 82.5%. The area under the receiver operating characteristic (AUROC) is 0.907, the cutoff value is 0.671, the sensitivity is 89.30%, the specificity is 77.80%, the positive predictive value is 90.34%, and the negative predictive value is 81.89%; (3) The AUROC of HBV-I in the validation group was 0.871 and the overall accuracy rate is 86.96%. Conclusion Our novel model HBV-I [combining CAP, LSM, lg (HBV DNA), and AST] shows promising utility for predicting HBV-I in patients with CBI with concurrent NAFLD with high sensitivity, accuracy, and repeatability, which may contribute to clinical application.

Natural History and Non-Invasive Diagnosis and Clinical Management of Chronic HBV Infection Overlapping with Non-Alcoholic Fatty Liver Disease

Hepatitis B Virus Infection Combined with Nonalcoholic Fatty Liver Disease: Interaction and Prognosis

Clinical Impact and Mechanisms of Hepatitis B Virus Infection Concurrent with Non-Alcoholic Fatty Liver Disease

Research progress of the impact of nonalcoholic fatty liver disease on chronic hepatitis B infection

The interplay between non-alcoholic fatty liver disease and innate immunity in hepatitis B virus patients

Chronic Hepatitis B and Non‐alcoholic Fatty Liver Disease: Conspirators or Competitors?

[Characteristics, Diagnostic and Therapeutic Strategies for Chronic Hepatitis B Combined with Non-Alcoholic Fatty Liver Disease].

A Novel Noninvasive Diagnostic Model of HBV-Related Inflammation in Chronic Hepatitis B Virus Infection Patients With Concurrent Nonalcoholic Fatty Liver Disease

Interaction Between Hepatitis B Virus Replication and Lipid Metabolism in Patients with Chronic Hepatitis B and NAFLD

Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients

Fatty liver is associated with significant liver inflammation and increases the burden of advanced fibrosis in chronic HBV infection

Fatty liver is associated with significant liver inflammation but does not increase fibrosis burden in Chronic HBV infection

[Research Advances in Diagnosis of Non-Alcoholic Fatty Liver Disease].

Fatty liver is associated with significant liver inflammation but does not increase fibrosis burden in Chronic Hepatitis B

Acute-on-chronic Liver Failure in Chronic Hepatitis B: an Update.

Metabolic Syndrome, Nonalcoholic Fatty Liver Disease, and Chronic Hepatitis B: A Narrative Review

Impact of NAFLD on the Outcome of Patients with Chronic Hepatitis B in Asia

The co-existence of NAFLD and CHB is associated with suboptimal viral and biochemical response to CHB antiviral therapy: a systematic review and meta-analysis

Effects of Chronic HBV Infection on Lipid Metabolism in Non-Alcoholic Fatty Liver Disease: A Lipidomic Analysis

Management of non-alcoholic fatty liver disease-associated hepatocellular carcinoma

Adverse Effect of Nonalcoholic Fatty Liver Disease on the Therapeutic Response in Patients with Chronic Hepatitis B